Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism

What Was Tested

Researchers studied Semaglutide in this randomized controlled trial publication.

To compare the effects of semaglutide and testosterone replacement therapy (TRT) on semen quality and parameters of functional hypogonadism (FH) in men with type 2 diabetes mellitus and obesity.

Who Took Part

The study group was 25 men.

PubMed indexes the participants as middle-aged adults, men only.

Semen analysis and parameters of FH were measured at baseline and after 24 weeks of treatment.

Participants completed questionnaires of the International Index of Erectile Function-15 (IIEF-15) and the Aging Symptoms in Men (AMS).

How the Study Was Run

The design is described as randomized and open-label.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

A time span of 24 weeks appears in the methods.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Testosterone, Obesity, Hypogonadism, Spermatozoa and Semen Analysis.

Author keywords: functional hypogonadism, semaglutide and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized and open-label study of Semaglutide in 25 men over 24 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.